Streetbeat News

Regulatory

HARP

Harpoon Therapeutics has completed planned patient enrollment in its Phase 1 study of HPN217 for relapsed/refractory multiple myeloma.

Portfolio Pulse from Bill Haddad

June 27, 2023 | 11:35 am

ARWR

Arrowhead Pharmaceuticals has filed for regulatory clearance to initiate a Phase 1 clinical trial of ARO-SOD1, an RNAi-based investigational medicine for treating amyotrophic lateral sclerosis (ALS) caused by SOD1 mutations. ARO-SOD1 is the first therapeutic candidate leveraging Arrowhead's TRiM platform for CNS delivery.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 11:35 am

ANVS

Annovis Bio, a clinical stage drug platform company, has announced the creation of a novel crystalline form of buntanetap (ANVS402) and filed a new composition of matter provisional patent with the U.S. Patent and Trademark Office.

Portfolio Pulse from Bill Haddad

June 27, 2023 | 11:32 am

BLK

BTCUSD

ARK Investment Management claims to be the first in line for approval of a spot-Bitcoin ETF, ahead of BlackRock. Other asset managers such as Invesco, WisdomTree, and Valkyrie have also filed applications for their own Bitcoin funds.

Portfolio Pulse from Mehab Qureshi

June 27, 2023 | 11:22 am

ACIU

AC Immune's stock is trading higher after the FDA granted fast track designation for its anti-amyloid-beta active immunotherapy, ACI-24.060, for Alzheimer's disease.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 11:16 am

FWBI

First Wave BioPharma has announced the publication of two patent applications for the composition of matter and methods of use claims governing its enhanced enteric microgranule delivery formulation of Adrulipase.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 11:11 am

BIIB

Alcyone Therapeutics announced a collaboration with Biogen for a pivotal FDA-approved trial of Alcyone's ThecaFlex DRx System to assess repeat intrathecal access, cerebrospinal fluid aspiration, and delivery of Spinraza (Nusinersen).

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 11:09 am

ALDX

Aldeyra Therapeutics reported positive top-line results from the Phase 2 clinical trial of orally administered ADX-629, showing a significant reduction in cough frequency compared to placebo. A Phase 2 trial for ADX-629 in moderate alcohol-associated hepatitis is expected to begin in H2 2023.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 11:07 am

NKTX

Nkarta reports updated data from its Phase 1 study of NKX101, an allogeneic cell therapy candidate, to treat patients with relapsed or refractory acute myeloid leukemia. The therapy uses NK cells derived from healthy donors and targets NKG2D ligands on cancer cells.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 11:03 am

ACIU

AC Immune has secured FDA Fast Track designation for its anti-amyloid-beta active immunotherapy, ACI-24.060, aimed at treating Alzheimer's disease.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 11:01 am